Suyu Shu

Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.

Adoptive Immunotherapy of Newly Induced Murine Sarcomas

Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.

In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.

Antitumor Efficacy of Lymphokine-activated Killer Cells and Recombinant Interleukin-2 in Vivo: Survival Benefit and Mechanisms of Tumor Escape in Mice Undergoing Immunotherapy

Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.

In Vitro Differentiation of T-Cells Capable of Mediating the Regression of Established Syngeneic Tumors in Mice